|  | CXCL13 |  |  | GPS |  |  |
---|---|---|---|---|---|---|---|
Characteristics | Â | Low | High | P | 0/1 | 2 | P |
Age (years) | ≤60 | 32 | 24 |  | 48 | 8 |  |
 | >60 | 3 | 10 | 0.034 | 6 | 7 | 0.005 |
Ann Arbor stage | I/II | 30 | 10 | Â | 37 | 3 | Â |
 | III/IV | 5 | 24 | <0.001 | 17 | 12 | 0.001 |
Serum LDH | Normal | 22 | 8 | Â | 28 | 2 | Â |
 | Increased | 13 | 26 | 0.001 | 26 | 13 | 0.009 |
B symptoms | Absence | 25 | 14 | Â | 35 | 4 | Â |
 | Presence | 10 | 20 | 0.015 | 19 | 11 | 0.017 |
LN involvement | Absence | 25 | 15 | Â | 36 | 4 | Â |
 | Presence | 10 | 19 | 0.029 | 18 | 11 | 0.008 |
Primary site | Nasal | 29 | 12 | Â | 38 | 3 | Â |
 | Extranasal | 6 | 22 | <0.001 | 16 | 12 | 0.001 |
Bone marrow invasion | No | 33 | 23 | Â | 49 | 7 | Â |
 | Yes | 2 | 11 | 0.006 | 5 | 8 | 0.001 |
Extranodal involvement | 0/1 | 29 | 14 | Â | 38 | 5 | Â |
 | ≥2 | 6 | 20 | <0.001 | 16 | 10 | 0.015 |
EBV DNA | Non-detectable | 29 | 13 | Â | 38 | 4 | Â |
 | Detectable | 6 | 21 | <0.001 | 16 | 11 | 0.006 |
IPI | L/LI | 30 | 14 | Â | 42 | 2 | Â |
 | HI/H | 5 | 20 | <0.001 | 12 | 13 | <0.001 |
NKPI | Group I/II | 22 | 4 | Â | 24 | 2 | Â |
 | Group III/IV | 13 | 30 | <0.001 | 30 | 13 | 0.036 |